Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 134Neoplasms 112Polycystic Ovary Syndrome 66Prostatic Neoplasms 63Colorectal Neoplasms 51Carcinoma, Non-Small-Cell Lung 46Pain 40Carcinoma, Hepatocellular 35Lung Neoplasms 34Keratosis, Actinic 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Neoplasm Metastasis 26Head and Neck Neoplasms 26Pain, Postoperative 25Stomach Neoplasms 24Colonic Neoplasms 23Multiple Myeloma 22Brain Neoplasms 21Pancreatic Neoplasms 20Lymphoma, Follicular 19Leukemia 19Anemia 19Uterine Cervical Neoplasms 18Leukemia, Myeloid, Acute 18Infertility 18Leiomyoma 17Lymphoma, Non-Hodgkin 16Lymphoma 16Cancer Pain 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Completed × Pituitary ACTH Hypersecretion × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡